期刊
JOURNAL OF CROHNS & COLITIS
卷 7, 期 8, 页码 653-669出版社
OXFORD UNIV PRESS
DOI: 10.1016/j.crohns.2013.02.005
关键词
Diagnosis; Monitoring; Imaging; Biomarkers; Endoscopy; Disease activity index
资金
- Abbott Laboratories
- Merck Sharp and Dohme Corp.
- UCB Pharma
- Janssen
- Takeda
- ActoGeniX
- Albireo Pharma
- Amgen
- AstraZeneca
- Bayer AG
- Biogen Idec
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb
- Cellerix
- Centocor
- ChennoCentryx
- Cosmo Technologies
- Danone Research
- Elan Pharmaceuticals
- Genetech
- Giuliani SpA
- Given Imaging
- GlaxoSmithKline
- Hutchison MediPharma
- Merck Sharp and Dohme Corp
- Neovacs
- Ocera Therapeutics Inc.
- Otsuka America Pharmaceutical
- Pfizer
- Shire Pharmaceuticals
- Prometheus Laboratories
- Sanofi-Aventis
- Schering-Plough
- Synta Pharmaceuticals Corp
- Teva
- Therakos
- Tillotts Pharma
- Wyeth
- Vifor Pharma
- Alba Therapeutics
- Atherys
- Axcan
- Celgene
- Elan /Biogen
- Genentech
- Given Imaging Inc.
- ISIS
- Janssen-Ortho
- Merck
- Ore Pharm
- Pfizer, Inc.
- Procter and Gamble
- Prometheus Therapeutics and Diagnostics
- Protein Design Labs
- Salix Pharmaceuticals
- Santarus
- Zeland Pharma
- Novo Nordisk
- Novartis
- MSD
- Ferring
- Schering Plough
- Essex
- UCB
- Falk
- Tygenics
Management of Crohn's disease has traditionally placed high value on subjective symptom assessment; however, it is increasingly appreciated that patient symptoms and objective parameters of inflammation can be disconnected. Therefore, strategies that objectively monitor inflammatory activity should be utilised throughout the disease course to optimise patient management. Initially, a thorough assessment of the severity, location and extent of disease is needed to ensure a correct diagnosis, identify any complications, help assess prognosis and select appropriate therapy. During follow-up, clinical decision-making should be driven by disease activity monitoring, with the aim of optimising treatment for tight disease control. However, few data exist to guide the choice of monitoring tools and the frequency of their use. Furthermore, adaption of monitoring strategies for symptomatic, asymptomatic and post-operative patients has not been well defined. The Annual excHangE on the ADvances in Inflammatory Bowel Disease (IBD Ahead) 2011 educational programme, which included approximately 600 gastroenterologists from 36 countries, has developed practice recommendations for the optimal monitoring of Crohn's disease based on evidence and/or expert opinion. These recommendations address the need to incorporate different modalities of disease assessment (symptom and endoscopic assessment, measurement of biomarkers of inflammatory activity and cross-sectional imaging) into robust monitoring. Furthermore, the importance of measuring and recording parameters in a standardised fashion to enable longitudinal evaluation of disease activity is highlighted. (C) 2013 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据